Is EPIRUS Biopharmaceuticals, Inc. (EPRSQ) a Buy, Sell, or Hold?
OTC : EPRSQ
EPIRUS Biopharmaceuticals, Inc.
$1e-06 USD
$0.0 (-99.01%)
- Volume
- 150
- Average Volume
- 15
- Market Capitalization
- $1.57K
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
OTC
Jeff Kagy
Biotechnology
Healthcare
EPRSQ
73
US
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Jeff Kagy | Vice President of Human Resources & Administration |
Poll Results
No votes yet today — be the first to share your view!
About EPIRUS Biopharmaceuticals, Inc. (OTC:EPRSQ) Stock
EPIRUS Biopharmaceuticals, Inc. was a global pharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of biosimilar therapeutics. Its primary experimental compound was BOW015, a biosimilar counterpart to Remicade (infliximab), intended for the treatment of various inflammatory conditions. The company's developmental portfolio also encompassed several other biosimilar candidates: BOW050, a biosimilar version of Humira (adalimumab), targeting inflammatory diseases such as rheumatoid arthritis, various adult and pediatric forms of arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis. BOW070, mimicking Actemra (tocilizumab), aimed at rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. ... BOW080, a biosimilar to Soliris, designed to address ultra-rare blood disorders like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. BOW100, a biosimilar of SIMPONI, for inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. EPIRUS had established strategic alliances, including a licensing arrangement with Sun Pharmaceutical Industries Ltd., a joint licensing and collaboration pact with Livzon Mabpharm Inc., and a collaborative venture with Polpharma S.A. Founded in 2011, the firm maintained its corporate base in Boston, Massachusetts. However, on July 25, 2016, Epirus Biopharmaceuticals, Inc. initiated Chapter 7 liquidation proceedings by submitting a voluntary petition with the US Bankruptcy Court for the District of Massachusetts.
Frequently Asked Questions
-
What is the current EPIRUS Biopharmaceuticals, Inc. (EPRSQ) stock price?
-
EPIRUS Biopharmaceuticals, Inc.(OTC:EPRSQ) stock price is $1e-06 in the last trading session. During the trading session, EPRSQ stock reached the peak price of $6 while $1.0E was the lowest point it dropped to. The percentage change in EPRSQ stock occurred in the recent session was --99.01% while the dollar amount for the price change in EPRSQ stock was -$0.0.
-
EPRSQ's industry and sector of operation?
-
The OTC listed EPRSQ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EPRSQ?
-
Jeff Kagy | Vice President of Human Resources & Administration
|
|
|
| -
How many employees does EPRSQ have?
-
Number of EPRSQ employees currently stands at 73. EPRSQ operates from 699 Boylston Street, Boston, MA 02116, US.
-
Link for EPRSQ official website?
-
Official Website of EPRSQ is: https://epirusbiopharma.com
-
How do I contact EPRSQ?
-
EPRSQ could be contacted at phone #617-600-3497 and can also be accessed through its website. EPRSQ operates from 699 Boylston Street, Boston, MA 02116, US.
-
How many shares of EPRSQ are traded daily?
-
The average number of EPRSQ shares traded daily for last 3 months was 15.
-
What is the market cap of EPRSQ currently?
-
The market value of EPRSQ currently stands at $1.57K with its latest stock price at $1e-06